Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nature's Answer

This article was originally published in The Tan Sheet

Executive Summary

KidEven and KidCentrate alcohol-free supplements added to the firm's For Kids product line. KidEven's structure/function claim says it "Promotes calmness," while KidCentrate "Promotes mental concentration," according to labeling. The products, multi-herbal liquid mixtures featuring rosemary leaf, retail for $13.99 in 4 oz. bottles. Dosages are based on age and weight. A similar child-targeted supplement for attention and memory was launched by Natrol in early August under the Kid's Companion name (1"The Tan Sheet" July 10, p. 11). In May, Efamol Nutraceuticals and J&R Research settled FTC charges over AD/HD claims on supplements (2"The Tan Sheet" May 15, p. 9)

You may also be interested in...



Natrol Kid's Companion Line Includes Attention/Memory Formula

Natrol will introduce a new line of multivitamins, as well as an attention/memory supplement, for children beginning in August. A print ad campaign for the Kid's Companion brand will break the same month the 10-SKU line hits store shelves.

Supplement Marketers Settle Attention Deficit Disorder Claims With FTC

Dietary supplement marketers Efamol Nutraceuticals and J&R Research have agreed to settle Federal Trade Commission charges that claims made for their products to treat attention deficit/hyperactivity disorder and other conditions and diseases are unsubstantiated.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel